Liječenje multiple skleroze

Other literature type English OPEN
Bošnjak-Pašić, Marija ; Vidrih, Branka ; Miškov, Snježana ; Demarin, Vida (2009)
  • Publisher: Sestre Milosrdnice University hospital and Institute of Clinical Medical Research
  • Journal: Acta clinica Croatica, volume 48, issue 3 (issn: 0353-9466, eissn: 1333-9451)
  • Subject: Multiple sclerosis - therapy; Immunosuppressive agents - therapeutic use; Interferon, beta - therapeutic use | Multipla skleroza - terapija;Imunosupresivi - terapijska primjena; Interferon, beta - terapijska primjena

Multiple sclerosis is an autoimmune inflammatory demyelinating disease of the central nervous system, characterized by multifocal inflammatory destruction of myelin, axonal damage and loss of oligodendrocytes. The disease is carried through two stages: inflammatory and degenerative. The most common form of disease in approximately 85% of the cases is RRMS (relapsing-remitting form). The treatment of MS is divided into: treatment of the acute phase of illness, prevention of new relapses and disease progression, and symptomatic treatment. Most of the changes in treatment of multiple sclerosis and most of the news in recent years concerning new drugs are used in the treatment of progression of the disease and prevention of disease relapses. Some of these drugs are registrated in most European countries and USA, and others are in various stages of research.
  • References (27)
    27 references, page 1 of 3

    1. Choffion M. Mechanisms of action for treatments in multiple sclerosis. Biodrugs 2005;19:299-308

    2. Isaacs A, Lindemann J. Virus interference. The interferon. Proc R Soc Lond (BioI) 1957;147;258-67

    3. Iz rada struene grupe za lijekove Ministarstva zdravstva Republike Hrvatske. Pharmaca 1997;35:49-60

    4. The IFNB MS Study Group.Interferon beta -Ib is effective in RRlVIS: clinical results of a multicentre, randomized, doubleblind, plecebo-controlled trial. Neurology 1993;43:665-61

    5. Filippini G, Munari L, Incorvaia B, Ebers GC, Polman C, DAmico R. Interferons in relapsing rmitting multiple sclerosis: a systematic review. Lancet 2003;361:545-52

    6. ShariefMK. Dose and frequency of administration of interferon-beta affect its efficacy in multiple sclerosis. Clin drug Investig 2003;23:551-9

    7. The PRISMS Study Group (Prevention of Relapses and Disability by Interferon Beta-la Subcutaneously in Multiple Sclerosis). Randomised double-blind placebo controlled study of interferon beta-la in relapsing/remitting multiple sclerosis . Lancet 1988;352:1498-504

    8. Jacobs LD, Cookfair DL, Rudick RA. Results of a phase III trialof intramuscular recombinant beta interferon as treatmentof mul tiple sclerosis. Ann NeuroI1994;36:256 ???

    9. Jacobs LD, Cookfair DL, Rudick RA. Intramuscular interferon-beta la for a disease progression in relapsing multiple sclerosis. Ann NeuroI1996;39:258-94

    10. IFNB MS Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I MRI analysis results of a multicentre, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-667

  • Metrics
    No metrics available
Share - Bookmark